Publications

by | February 27, 2012 | Uncategorized

Third Information to Patients proposal from the European Commission: more information, less advertising?

On 10 February 2012, the European Commission presented for the third time legislative proposals for the Information to Patients component of the pharmaceutical package, which will put in place rules governing information on prescription drugs and surveillance of possible side effects of such medicines. The latest proposals continue to uphold Europe’s ban on direct-to-consumer advertising and further restrict internet marketing by pharmaceutical companies.

The proposals follow European Commissioner for Health and Consumer Policy John Dalli’s announcement in December that the amendments presented in October 2011 would be split in two to focus on information to patients and pharmacovigilance, after concerns raised by Member States.

The proposals address some of the concerns voiced by EPHA following the October 2011 proposals

– [->art4775]

Main elements

– They continue to place emphasis on the patient, based on the principle that the patient should have to request information before receiving it, and not the opposite.

– They determine the type of information to be provided (making a distinction between information and advertising) and limit the channels through which such information may be communicated.

– Regarding the internet, it is proposed that registered websites for objective and non-promotional information are necessary and specific rules on the monitoring of those websites should be established to take account of the cross-border nature of information provided over the internet and to allow cooperation between the Member States.

– They also provide that the information must be controlled by the competent authorities, in particular in the framework of the procedure for authorisation for placing on the market, and abolish the possibility for Member States to choose voluntary controls by self-regulation or co-regulation bodies.

– The proposals nevertheless maintain derogations for Member States that cannot set up a prior control system for constitutional reasons related to the principles of freedom of expression and freedom of the press.

– Registered websites for objective and non-promotional information will be established, and specific rules on their monitoring should be established given the cross-border nature the internet and need for cooperation between Member States. Pharmaceutical companies may link their websites to EU databases and portals on medicinal products, e.g. the forthcoming EU medicines web-portal, the main point of access for information on medicines expected to be online in July 2012. A network of sites shall promote the rational and safe use of medicines and directs users to relevant EU and national websites.

The EPHA Working Group on Pharmaceutical Policy will discuss the latest ITP proposals, which are now going to the European Parliament and the Council of the European Union.

——

Further information

– Amended Commission proposal for a Directive as regards information to the general public on medicinal products subject to medical prescription

– [Amended Commission proposal for a Regulation as regards information to the general public on medicinal products subject to medical prescription
->https://ec.europa.eu/health/files/patients/2012_reg_medical-prescription_prop/reg_medical-prescription_prop_2012_en.pdf]

EPHA related articles

– [->art5000]
– [->art4967]
– [->art4782]
– [->art3925]
– [->art3825]
– [->art3776]

Get the EPHA Newsletter

The best of our activities, right in your inbox!